FDA Issues Class III Recall for Orient Pharma's Pitavastatin Tablets Over Degradation Issues
Orient Pharma Co., Ltd. Yunlin Plant faces a Class III FDA recall for 20,618 bottles of Pitavastatin Tablets, 1 mg, due to failed impurities/degradation specifications. This voluntary, firm-initiated action impacts Teva Pharmaceuticals' supply, highlighting critical quality control vulnerabilities in contract manufacturing. Procurement and regulatory teams must scrutinize existing supplier qualifications and enhance stability monitoring for Pitavastatin Calcium, assessing immediate supply chain risks and long-term compliance strategies.
FDA Initiates Class III Recall for Orient Pharma's Pitavastatin Tablets
The U.S. Food and Drug Administration (FDA) has announced a Class III recall for Pitavastatin Tablets, 1 mg, manufactured by Orient Pharma Co., Ltd. Yunlin Plant in Yunlin County, Taiwan. This voluntary, firm-initiated recall, identified as D-0527-2025, commenced on June 11, 2025, and is categorized due to the product failing impurities/degradation specifications. A total of 20,618 bottles of this human prescription drug are affected, distributed primarily to New Jersey, USA. For procurement directors, this event necessitates an immediate assessment of current inventory and supply chain resilience for Pitavastatin Calcium. The affected product, marketed for Teva Pharmaceuticals, Parsippany, NJ 07054, includes multiple NDC codes: 0480-3631-98, 0480-3632-98, and 0480-3633-98. Specific lots, such as P051001, P051002, P051003 (Exp Date 07/2025), P051005, P051006 (Exp Date 10/2025), P051007 (Exp Date 01/2026), P051010 (Exp Date 07/2026), P051011, P051012 (Exp Date 09/2026), and P051013, P051014, P051015 (Exp Date 01/2027), are implicated. Regulatory affairs heads must monitor the FDA's ongoing oversight of this recall, understanding that even Class III recalls, while posing a remote probability of adverse health consequences, signify a breach in quality standards that demands immediate attention and corrective action from the manufacturer.
Orient Pharma's Manufacturing Role and Teva's Supply Chain Exposure
Orient Pharma Co., Ltd. Yunlin Plant, located at No. 8 Kehu 1st Rd., Huwei Township, Yunlin County, Taiwan, serves as a contract manufacturing organization (CMO) for Teva Pharmaceuticals, producing Pitavastatin Tablets, 1 mg. This relationship underscores the critical reliance on third-party manufacturers within the global pharmaceutical supply chain. The recall directly impacts Teva's ability to supply Pitavastatin, a crucial statin for cholesterol management, under its ANDA205932. This situation highlights the inherent risks associated with outsourcing production, particularly when a single facility is responsible for a significant portion of a product's supply. For supply chain VPs, this incident serves as a stark reminder of the imperative for robust vendor qualification and ongoing oversight programs for CMOs. A quality failure at a manufacturing partner, even for a Class III issue, can lead to significant market disruption, reputational damage, and financial losses for the marketing authorization holder. Business development executives should note that such supply disruptions can create opportunities for competitors to gain market share if Teva faces prolonged challenges in securing compliant Pitavastatin Calcium supplies. The geographic concentration of manufacturing in Taiwan also prompts a review of regional supply chain diversification strategies to mitigate country-specific risks.
Critical Quality Failure: Implications for Product Integrity and Patient Safety
The core issue, "Failed Impurities/Degradation Specifications," points to fundamental problems in Orient Pharma's quality management system, specifically concerning product stability and impurity control. Degradation products can arise from various factors, including inadequate manufacturing processes, improper storage conditions, or insufficient stability testing protocols. While a Class III recall indicates a remote probability of serious adverse health consequences, any deviation from established impurity limits is a serious breach of Good Manufacturing Practices (GMP) and can compromise the drug's efficacy and safety profile over its shelf life. For regulatory affairs heads, this necessitates a thorough review of stability data, impurity profiles, and quality control procedures for all pharmaceutical products, especially generic formulations of Pitavastatin Calcium. Such failures can trigger increased scrutiny from regulatory bodies like the FDA, potentially leading to more extensive inspections or future regulatory actions. Procurement teams must understand that a supplier's inability to meet degradation specifications reflects a systemic quality issue that could affect other products or batches. This event underscores the need for rigorous incoming material testing, in-process controls, and finished product release criteria to ensure that all active pharmaceutical ingredients (APIs) and finished drug products consistently meet stringent quality attributes throughout their lifecycle.
Strategic Procurement and Regulatory Mitigation in a Dynamic Landscape
In response to this recall, procurement directors must immediately initiate a comprehensive risk assessment of their Pitavastatin Calcium supply chain, focusing on potential single points of failure and the qualification status of alternative manufacturers. Given the lack of specific alternative supplier data in our current knowledge graph for Orient Pharma, companies reliant on this source for Pitavastatin will need to proactively identify and qualify new suppliers, a process that can be lengthy and resource-intensive. This involves not only technical qualification but also rigorous auditing of quality systems and regulatory compliance history. For supply chain VPs, this event reinforces the importance of implementing robust business continuity plans and diversifying supplier bases to minimize disruption. Regulatory affairs teams should prepare for potential inquiries from health authorities regarding their due diligence processes for CMOs and their strategies for managing product quality risks. The "ongoing" status of the recall means continued vigilance is required. Companies must ensure their quality agreements with CMOs explicitly define responsibilities for stability monitoring, impurity control, and recall procedures, thereby safeguarding product integrity and maintaining uninterrupted patient access to essential medicines like Pitavastatin.